Opdivo

PsiOxus Therapeutics Ltd has updated the agreement to advance its clinical collaboration with Bristol-Myers Squibb Co (NYSE: BMY) to evaluate PsiOxus' tumor re-engineering platform, in combination with BMY's Opdivo (nivolumab) to treat a range of tumor types....

Two big pharma titans are battling for supremacy in the field of oncology immunotherapy. From the looks of it, Kenilworth, New Jersey-based Merck & Co., Inc. (NYSE: MRK) may have the upper hand over Bristol-Myers Squibb Co (NYSE: BMY). Before poring over the specifics, here's what...

Bristol-Myers Squibb Co (NYSE: BMY), which is prepping for its purchase of Celgene Corporation (NASDAQ: CELG), announced Thursday that its cancer immunotherapy drug Opdivo failed in a late-stage study evaluating it as a brain cancer treatment.  Primary Endpoint Not Met Bristol-...

Bristol-Myers Squibb Co (NYSE: BMY) shares are sliding Thursday despite the company reporting forecast-beating Q4 results. The negative sentiment could be traced back to a regulatory update the company issued for its cancer drug combo that is being evaluated for lung cancer. What Happened Bristol-...

Biotech stocks had a fairly decent run up in July after a nearly flat performance in June. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) is up about 5 percent. As the earnings season kicks into high gear and amid several other catalysts, August is likely to be an action-packed...

The U.S. Food and Drug Administration issued an alert on issues discovered in ongoing studies of Merck & Co., Inc. (NYSE: MRK)’s Keytruda Roche’s Tecentriq, according to a headline from Bloomberg. Regulators reportedly found that some patients had decreased survival. Why It’...

The biotech space wasn't immune to the broader market sell-off in March, although the degree of negativity was less pronounced among defensive biotech stocks. Rising demand for drugs, as the population ages, the prospects of the FDA expediting approval process as the Trump administration...

The FDA decided favorably on four of the six major PDUFA decisions due in February, with Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s Salix Pharma unit and its partner Norgine announcing an extension the PDUFA action date for Plenvu by three months to May 13, 2018, citing the time needed to...

The number of biotech stocks posting gains outstripped those recording losses for the week. Notable among the gainers for the week were Odonate Therapeutics Inc (NASDAQ: ODT) — which reported its financial results Feb. 14 and has been rallying ever since — and ARMO Biosciences Inc...

Bristol-Myers Squibb Co (NYSE: BMY) stock is up 26.5 percent year-over-year, making a partial recovery from a mid-2016 plunge, and one analyst anticipates upside worthy of a new all-time high. The Rating Morgan Stanley analyst David Risinger upgraded Bristol-Myers from Equal-Weight to Overweight...

Jefferies said in a note Monday that upside asymmetry for Bristol-Myers Squibb Co (NYSE: BMY) is exhausted at current levels, with shares having already discounted M&A spec and biopharma flows. This, according to the firm, leaves significant downside risk if current study CM-227 fails. CM-...

Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares are skyrocketing Friday in reaction to its announcement of positive preliminary data from two ongoing clinical trials of its non-small cell lung cancer, or NSCLC, candidate sitravatinib. The company said the data will be presented at the IASLC 2017...

The American Society of Clinical Oncology, or ASCO, has scheduled its annual meeting on June 2–6, 2017, at McCormick Place, Chicago. The five-day event has Conquer Cancer Foundation as its lead sponsor. The event, typically attended by over 30,000, will be marked by presentations of...

Earnings season has always been a market-moving catalyst for stocks. Depending on the numbers and their quality, stocks could swing wildly in either direction and create volatility — not a palatable proposition for traders. The risk is always there. However, one can trade the volatility by...

Billionaire investor and corporate raider Carl Icahn has trained his eyes on Bristol-Myers Squibb Co (NYSE: BMY). A Wall Street Journal report revealed on Tuesday that Icahn has picked up a substantial stake in the pharma giant, although the report did not put a number to it. Does Icahn's...